Home / Letter From The Editor / Oct. 22, 2019

Oct. 22, 2019

Oct 22, 2019
 

It has been a dozen years since Dr. Steven Nissen took direct aim at pioglitazone and rosiglitazone, based on his interpretation of cardiac risk factors. The FDA rushed to put severe restriction on their usage and finally in 2010 rosiglitazone, also known as Avandia, was withdrawn from the market. Pioglitazone was still prescribed, but a once blockbuster drug was reduced to a small market share.

Fast forward the clock a couple of years and the FDA almost totally reverses its opinion and in an “oops” moment admits that they overreacted.

 

Now it is 2019 and our intern Taylor-Eugene Simmons, Florida A&M University, College of Pharmacy & Pharmaceutical Sciences, PharmD Candidate, has found extensive research that these same TZD’s are cardio protective and can serve a valuable role in improving glucose levels in type 2 diabetes patients. This worth reading a couple of times.

 

 

Dave Joffe

Editor-in-chief